Purified herpes simplex thymidine kinase RetrovectorTM particles. I. in vitro characterization, in situ transduction efficiency, and histopathological analyses of gene therapy-treated brain tumors

Cancer Gene Therapy

Volumn 4, Issue 2, 1997, Pages 118-128

  Kruse, Carol A ^a   Roper, Michael D ^a   Kleinschmidt DeMasters, Bette K ^a   Banuelos, Scott J ^a   Smiley, W Russell ^b   Robbins, Joan M ^b   Burrows, Francis J ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Astrocytoma; Brain tumor; Glioblastoma; Retroviral vectors; Suicide gene therapy

Indexed keywords

ANTIBIOTIC G 418; ANTIMETABOLITE; BETA GALACTOSIDASE; GANCICLOVIR; GENTAMICIN; HEXADIMETHRINE BROMIDE; THYMIDINE KINASE;

ANIMAL; ARTICLE; BRAIN TUMOR; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIVISION; CHEMISTRY; DRUG EFFECT; ENZYMOLOGY; EXPERIMENTAL NEOPLASM; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HERPES SIMPLEX VIRUS; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; METHODOLOGY; PATHOLOGY; RAT; RAT STRAIN; RETROVIRUS;

ANIMALS; ANTIMETABOLITES; BETA-GALACTOSIDASE; BRAIN NEOPLASMS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIVISION; GANCICLOVIR; GENE THERAPY; GENETIC VECTORS; GENTAMICINS; HEXADIMETHRINE; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASMS, EXPERIMENTAL; RATS; RATS, INBRED STRAINS; RETROVIRIDAE; SIMPLEXVIRUS; THYMIDINE KINASE; TRANSDUCTION, GENETIC;

EID: 0031087213     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vectorproducer cells for treatment of experimental brain tumors. Science. 1992;256:1550-1552.
2. Ram Z, Culver KW, Walbridge S, Blaese RM, Oldfield EH. In situ retroviral-mediated gene transfer for the treatment of brain tumors. Cancer Res. 1993;53:83-88.
3. Tapscott SJ, Miller AD, Olson JM, Berger MS, Groudine M, Spence AM. Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection. Proc Nail Acad Sci USA. 1994;91: 8185-8189.
4. Chen SH, Shine HD, Goodman JC, Grossman RG, Woo SLC. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA. 1994;91:3054-3057.
5. Burrows FB, Smiley WR, Howard BD, Marsden R, Laubert B, Jolly DJ. High transduction efficiency and potent antitumor effects of purified HSV-TK Retrovectors against established murine and human solid tumors. Cancer Gene Ther. 1995;2:333.
6. Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol. 1990;10: 4239-4242.
7. Oshiro EM, Viola JJ, Oldfield EH, Walbridge S, Bacher J, Frank JA, Blacse RM, Ram Z. Toxicity studies and distribution dynamics of retroviral vectors following intrathecal administration of retroviral vector-producer cells. Cancer Gene Ther. 1995;2:87-95.
8. Crystal RG. Transfer of genes to humans: early lessons and obstacles to success. Science. 1995;270:404-410.
9. Oldfield EH. NIH Recombinant DNA Advisory Committee, June 1995, reports 9206-019 and 9312-059.
10. Purcell DF, Broscius CM, Vanin EF, Bucker CE, Nienhuis AW, Martin MA. An array of murine leukemia virus-related elements is transmitted and expressed in a primate recipient of retroviral gene transfer. J Virol. 1996;70:887-897.
11. Enquist LW, Vande Woude GF, Wagner M, Smiley JR, Summers WC. Construction and characterization of a recombinant plasmid encoding the gene for the thymidine kinase of herpes simplex type 1 virus. Gene. 1979;7:335-342.
12. Wagner MS, Sharp JA, Summers WC. Nucleotide sequence of the thymidine kinase gene of herpes simplex virus type 1. Proc Natl Acad Sci USA. 1981;78:1441-1445.
13. Armentano D, Yu S-F, Kantoff PW, von Ruden T, Anderson WF, Gilboa E. Effect of internal viral sequences on the utility of retroviral vectors. J Virol. 1987;61:1647-1650.
14. Chada S, DeJesus CE, Townsend K, Lee WTL, Laube L, Jolly DJ, Chang SMW, Warner JF. Cross-reactive lysis of human targets infected with prototypic and clinical human immunodeficiency virus type 1 (HIV-1) strains by murine anti-HIV-1 IIIB env-specific cytotoxic T lymphocytes. J Virol. 1993;67:3409-3417.
15. Burns JC, Friedmann T, Driever W, Burrascano M, Yu JK. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient germ transfer into mammalian and non-mammalian cells. Proc Natl Acad Sci USA. 1993;90:8033-8037.
16. Irwin MS, Laube LS, Lee V, Austin M, Chada S, Anderson G-G, Townsend K, Jolly DJ, Warner JF. Direct injection of a recombinant retroviral vector induces human immunodeficiency virus-specific immune responses in mice and non-human primates. J Virol. 1994;68:5036-5044.
17. Mitchell DH, Kruse CA, Withrow S, Johnston MR. Human recombinant interleukin-2 activated lymphocytes from normal and lung tumor-bearing dogs: cytotoxicity against autologous, allogeneic, and xenogeneic tumor targets. Am J Vet Res. 1991;52:1132-1136.
18. Kruse CA, Mitchell DH, Kleinschmidt-DeMasters BK, Franklin WA, Morse HG, Spector EB, Lillehei KO. Characterization of a continuous human glioma cell line DBTRG-05MG: growth kinetics, karyotype, receptor expression, and tumor suppressor gene analyses. In Vitro Cell Dev Biol. 1992;28A:609-614.
19. Kruse CA, Mitchell DH, Kleinschmidt-DeMasters BK, Bellgrau D, Eule JM, Parra JR, Kong Q, Lillehei KO. Systemic chemotherapy combined with local adoptive immunotherapy cures rats bearing 9L gliosarcoma. J Neurooncol. 1993;15:97-112.
20. Laws ER Jr, Thapar K. Brain tumors. CA. 1993;43:263-271.
21. Lampson LA, Wen P, Roman VA, Morris JH, Sarid JA. Disseminating tumor cells and their interactions with leukocytes visualized in the brain. Cancer Res. 1992;52: 1018-1025.
22. Kim JH, Kim SH, Kolozsvary A, Brown SL, Kim OB, Freytag SO. Selective enhancement of radiation response of herpes simplex virus thymidine kinase transduced 9L gliosarcoma cells in vitro and in vivo by antiviral agents. Int J Radiat Oncol Biol Phys. 1995;33:861-868.
23. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, Abraham GN. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993;53:5274-5283.
24. Caruso M, Panis Y, Gagandeep S, Houssin D, Salzmann J-L, Klatzmann D. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci USA. 1993;90:7024-7028.
25. Barba D, Hardin J, Sadelain M, Gage F. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci USA. 1994;91:4348-4352.
26. Rainov NG, Kramm CM, Aboody-Guterman K, Chase M, Ueki K, Louis DM, Harsh GR IV, Chiocca EA, Breakefield XO. Retrovirus-mediated gene therapy of experimental brain neoplasms using the herpes simplex virus-thymidine kinase/ganciclovir paradigm. Cancer Gene Ther. 1996; 3:99-106.
27. Ram Z, Walbridge S, Shawker T, Culver KW, Blaese RM, Oldfield EH. The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. J Neurosurg. 1994;80:256-260.
28. Gagandeep S, Brew R, Green B, Christmas SE, Klatzmann D, Poston GJ, Kinsella AR. Prodrug-activated gene therapy: involvment of an immunological component in the "bystander effect." Cancer Gene Ther. 1996;3:83-88.
29. Consalvo M, Mullen CA, Mosesti A, Musiani P, Allione A, Cavallo F, Giovarelli M, Forni G. 5-Fluorocytosine-in-duced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. J Immunol. 1995;154:5302-5312.
30. Vile RG, Nelson JA, Castleden S, Chong H, Hart IR. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res. 1994;54:6228-6234.
31. Boviatsis EJ, Chase M, Wei MX, Tamiya T, Hurford Jr RK, Kowall NW, Tepper RI, Breakefield XO, Chiocca EA. Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors. Hum Gene Ther. 1994;5:183-191.
32. Blume MR, Wilson CB, Vasquez DA. Immune response to a transplantable intracerebral glioma in rats. In: Sane K, Ishi S, Le Vay D, eds. Recent Progress in Neurologic Surgery, Amsterdam: Excerpta Medica; 1974:129-132.
33. Mahaley MS, Gillespie GY. Immunotherapy of patients with glioma: fact, fancy and future. Prog Exp Tumor Res. 1984;28:118-135.
34. Kruse CA, Molleston MC, Parks EP, Schiltz PM, Kleinschmidt-DeMasters BK, Hickey WF. A rat glioma model, CNS-1, with invasive characteristics similar to those of human gliomas: a comparison to 9L gliosarcoma. J Neurooncol. 1994;22:191-200.